<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Sana Biotechnology ( (SANA) ) has provided an update. On May 15, 2026, Sana Biotechnology, Inc. reported that it had sold a total of 21,607,878 shares of its common stock under an amended and restated sales agreement with TD Securities (USA) LLC, which acted as the sales agent. The transaction generated approximately $69.0 million in net proceeds, strengthening the company’s cash position and providing additional funding capacity for its ongoing operations and strategic programs. This equity financing reflects Sana Biotechnology’s continued reliance on capital markets to support its development pipeline and broader corporate objectives. The size of the offering and the engagement of a major securities firm underscore the company’s efforts to secure resources needed for long-term growth and execution in the competitive biotechnology sector. The most recent analyst rating on (SANA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page. Spark’s Take on SANA Stock According to Spark, TipRanks’ AI Analyst, SANA is a Neutral. The score is held down primarily by weak financial performance (no revenue, large losses, and ongoing cash burn) and a technically weak price trend below key moving averages. Offsetting these negatives, recent corporate events (Mayo strategic investment and financing flexibility) modestly improve near-term funding outlook, but do not fully mitigate the underlying profitability and dilution risks. To see Spark’s full report on SANA stock, click here. More about Sana Biotechnology Sana Biotechnology, Inc. is a biotechnology company focused on developing novel cell and gene engineering therapies. The company operates within the life sciences sector, raising capital through equity offerings to support its research, development, and potential commercialization activities in advanced therapeutics. Average Trading Volume: 3,325,217 Technical Sentiment Signal: Sell Current Market Cap: $873.8M </div>

SANA

SBIO

IBBQ

LABU

Sana Biotechnology, Inc. raised approximately $69 million by selling 21,607,878 shares of common stock under an agreement with TD Securities. This equity offering aims to enhance the company's cash position and support its ongoing operations and strategic initiatives. Despite a recent analyst rating of 'Buy' with a $7.00 price target, concerns about weak financial performance and dilution risks persist.

Tip Ranks

Sana Biotechnology

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Toronto Dominion Bank

Sana Biotechnology Raises $69 Million Through Equity Offering